Turnstone Biologics Q2 EPS $(0.92) Misses $(0.84) Estimate
Portfolio Pulse from Benzinga Newsdesk
Turnstone Biologics (NASDAQ:TSBX) reported a Q2 EPS of $(0.92), missing the analyst consensus estimate of $(0.84) by 9.52%. This represents an 87.83% improvement over the $(7.56) per share loss from the same period last year.
August 14, 2024 | 8:13 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Turnstone Biologics reported a Q2 EPS of $(0.92), missing the analyst estimate of $(0.84) by 9.52%. Despite the miss, the loss is significantly lower than the $(7.56) per share loss from the same period last year, showing an 87.83% improvement.
The EPS miss is likely to have a negative short-term impact on the stock price as it fell short of analyst expectations. However, the significant improvement from last year's loss may mitigate some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100